Clinical Trial

BLIND TRIAL OF A DEGRATED CARRAGEEININ AND ALUMINIUM HYDROXIDE GEL IN THE TREATMENT OF PEPTIC ULCERATION

P. R. C. EVANS, M.D., M.R.C.P.
S. NOWELL, F.F.R.
I. A. P. THOMAS, F.F.R.
Wrexham Group of Hospitals

Much experimental work and a few clinical studies have been devoted to the anti-ulcer properties of sulphated polysaccharides (Babkin and Komarov, 1932; Schiffrian and Warren, 1942; Wolf and Wolff, 1943; Watt, 1959). Ebimar (Evans Medical Ltd.) is such a substance derived from seaweed (Chondrus Crispus or Gigartina Stellate). Ebimar is based on carrageenan, a sulphated polygalactose. It is produced by depolymerising a crude extract of carrageenan, using phosphoric acid and hydrogen peroxide. This reduces the molecular weight of carrageenan from 100,000-700,000 to about 20,000. By this process viscosity and gel formation are greatly reduced, making it easier to administer to patients. It is thought that ebimar consists largely of lambda-carrageenan and it has a sulphate content of 31% (Personal communication from Evans Medical Ltd.). Ebimar has been shown to combine with protein substrate and protects the substrate from peptic digestion. Gastric mucus, protein foods and the protein on an ulcer floor are acted upon in this way (Anderson and Watt, 1959a, b, c; Bonfils, Dubrasquet and Lamblinger, 1959, 1960; Houck, Bhayana and Lee, 1960; Bonfils and Lamblinger, 1960a).

Watt and Marcus (in preparation), using a metachromatic stain, demonstrated that after oral administration of ebimar, prior to gastrectomy in humans, the substance was found in strands of mucus adherent to the gastric mucosa. Acid facilitates the formation of this complex, which has pepsin-inhibiting properties.

In uncontrolled clinical trials of ebimar, Bonfils and Lamblinger (1960b) treated 32 peptic ulcer patients who had failed to respond to other medicinai therapy. They were impressed with the results and so were Lamblinger, Bonfils, Kess and Simonpoli (1960), who followed patients for up to 18 months. Both these papers emphasise the importance of dosage and the frequency of administration of the substance. Berthet (1961), Esposito (1962) and de Landazuri, Badell and Badell and Conchillo (1961) also reported favourably on ebimar. The latter advocate sucking the tablets. Esposito and Nicolini (1961) showed that in patients with a raised blood pepsinogen ebimar caused a return towards normal levels.

In 1959 we started a double blind trial of ebimar and aluminium hydroxide gel in the treatment of peptic ulceration.

Method

Patients with a radiologically proven gastric or duodenal ulcer, who agreed to join the trial, had their names added to a list which determined at random what treatment they would receive. All patients were rested for the first four weeks and were advised to keep to a generous dyspepsia diet throughout the trial. They were seen at the outpatient clinic weekly for the first month and then once a month. Patients with gastric ulceration had mothly barium meal X-ray examinations until healing was complete, whilst those with duodenal ulceration were re-X-rayed approximately every three months. Whenever possible repeat X-ray examinations were undertaken by the same radiologist.

The patients were given either ebimar 1 g. or aluminium hydroxide gel 0.7 g. tablets, to be chewed and swallowed half way between each meal and three times this dose last thing at night. Every three months the treatment was switched. The two preparations were known by a code number and the clinician and radiologists were unaware which treatment the patients were receiving until after the final analysis of the results.

Clinical assessment at each interview was made as follows:
Grade A—no pain or other symptoms
Grade B—minor pain and/or occasional vomiting
Grade C—severe pain and/or frequent vomiting.

Material

The series consisted of 11 females and 24 males with duodenal ulceration (average age 40 years, range 16-65) and five patients with gastric ulceration (two females and three males, age 27-72 years).

Results

There was no difference in the average weight increase in the two groups. One patient on ebimar complained of mild diarrhea and 3 complained of constipation. Amongst those on aluminium hydroxide 6 complained of constipation, one of whom became so constipated that he had to be switched to ebimar.

Fig. 1 gives the periodical clinical assessment for the series. During the period one patient treated with ebimar was referred for surgery because of continuing pain and vomiting after two months (included in Fig. 1 as having severe pain).
Figure 1

A. Al₂O₃ FIRST

Number in Trial

% 100

Al₂O₃

EBIMAR

KEY

\[ \text{NO SYMPTOMS} \]

\[ \text{SLIGHT PAIN AND/OR OCCASIONAL VOMITING} \]

\[ \text{SEVERE PAIN AND/OR FREQUENT VOMITING} \]

B. EBIMAR FIRST

Number in Trial

% 100

EBIMAR

Al₂O₃

Fig. 1
Fig. 1 suggests that initial treatment with aluminium hydroxide gave better results than initial treatment with ebimar; but later treatment with ebimar may have had a small advantage. This latter view is slightly supported by the few follow-up interviews at 7, 8, 9 and 10 months, as during this period 8 interviews of patients on ebimar recorded that the patients were symptom-free. Those on aluminium hydroxide reported at 10 interviews that they had been symptom-free during the last month, but there were 5 interviews when minor pain and/or occasional vomiting was noted, no definite conclusions can be reached, however, because of the small numbers.

The 5 patients with gastric ulceration were all symptom-free and radiologically healed by the 3rd month, irrespective of which treatment they had received.

If radiology at the initial examination of a patient with duodenal ulceration showed a definite ulcer crater, subsequent barium meals showed that there was a preponderance of non-healing ulcers with either treatment. No significant difference between the healing properties of ebimar and aluminium hydroxide was found.

In view of these indecisive findings (which were not analysed statistically, as the numbers were so small), the beneficial effects of ebimar in some cases and the importance given in the literature to dosage and method of administration, it was decided to undertake a second trial amongst new consenting patients.

**Method**

The original diet was used and again the clinician and radiologists were unaware which treatment the patients were receiving. Tablets of ebimar 0.5 g. and aluminium hydroxide gel 0.7 g. were used. The patients were told to place a tablet between the upper gum and cheek and allow it to dissolve slowly (if possible without chewing) at the following times: on waking, 1 hour after breakfast, 1 hour before and 1 hour after the mid-day meal, 1 hour before and 1 hour after the evening meal and also prior to retiring for the night. They were advised to take an extra tablet after alcohol and were encouraged to spend the first 2 weeks away from work, resting as much as possible. All patients were seen at the clinic every 2 weeks for the first month and subsequently once a month. The radiological arrangements were the same as in the first trial.

In this trial the analysis of results was undertaken by an independent statistician who used a different method of clinical assessment. The data from the original case records were abstracted, tabulated, transferred to cards and analysed statistically. Until all calculations were completed only the code numbers of the two treatments were known to those working out the results. Scores of 0 to 4 were given for the severity and also for the frequency of pain, absence of pain scoring 0 and very severe or frequent pain scoring 4. The scores for each patient in each group was divided by twice the number of patients in that group.

**Material**

Assessments could be made from the records of 26 patients who had received aluminium hydroxide continuously and from 27 patients who had taken ebimar continuously. All these patients had radiological evidence of an active ulcer at the start of the trial. Table 1 shows that the patients receiving the two treatments were reasonably matched for diagnosis, age and sex.

The patients on ebimar were followed up for an average of 9.6 months (2-18 months) and those on aluminium hydroxide for an average of 9.8 months (1-18 months). Patients who had a hiatal hernia were not included in the trial. Surgery was resorted to (after 1 month) on 1 patient with a duodenal ulcer taking aluminium hydroxide and (after 14 months) on 1 patient with a gastric ulcer taking ebimar.

**Results**

*Pain.* Table 2 gives the patients' own reports about pain before and at the end of the trial. It shows that 7 patients receiving ebimar still had frequent or severe pain at the last assessment, whilst the figure for aluminium hydroxide was 2. Fourteen patients on ebimar and 17 on aluminium hydroxide had no pain at the final interview.

The mean score at the beginning for those on ebimar was 4.43 and for those on aluminium hydroxide 4.22, the final scores for the whole period being 2.11 and 1.11 respectively. This reduction was significant at the level of P<0.05 for both types of treatment but the difference between the two throughout the period of observation was not significant (t=1.68, P≈0.1).

*Weight changes* were similar in the two groups.

*Bowel habits.* No melena was recorded in either group, and 1 patient in each group complained of diarrhoea. 5 patients on ebimar had constipation and 13 on aluminium hydroxide. This difference was statistically significant (Gran Chi, or x²=5.12, P≈0.02).

*Radiological changes.* Barium meal X-ray examinations were performed at rather irregular intervals, owing to pressure of work on the Department; the division of the trial into 5-month periods is somewhat arbitrary, but it is the most logical one that can be made.

The difference between those with no ulcer seen after 5 months, calculated by a 2 x 2 chi squared table with a correction for continuity, was statistically just significant in favour of aluminium hydroxide (x²=4.06, P<0.05). The results at the end of the trial showed no difference, as far as complete healing was concerned, between the two groups (x²=1.53, P>0.10). If those are included who were radiologically improved at the end of the experiment, 80% benefited from ebimar and 68% from aluminium hydroxide, but these differences were again not significant. The conclusion therefore is that there was some radiological evidence in favour of aluminium hydroxide after 5 months of treatment.
### TABLE 1

**DIAGNOSIS, AGE AND SEX OF THE PATIENTS ON EACH TREATMENT**

<table>
<thead>
<tr>
<th>Tablet</th>
<th>Sex</th>
<th>Age</th>
<th>Duodenal</th>
<th>Gastric</th>
<th>Both</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Under 30</td>
<td>9</td>
<td>9</td>
<td></td>
<td>18</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>30-50</td>
<td>6</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Over 50</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>17</td>
<td>0</td>
<td>1</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>Under 30</td>
<td>4</td>
<td>1</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>30-50</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Over 50</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>5</td>
<td>3</td>
<td>1</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Under 30</td>
<td>7</td>
<td>1</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>30-50</td>
<td>11</td>
<td>1</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Over 50</td>
<td>2</td>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>20</td>
<td>2</td>
<td>0</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>Under 30</td>
<td>3</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30-50</td>
<td>3</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Over 50</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>22</td>
<td>3</td>
<td>1</td>
<td>26</td>
</tr>
</tbody>
</table>

### TABLE 2

**NUMBER OF PATIENTS REPORTING PAIN**

<table>
<thead>
<tr>
<th>Tablet</th>
<th>Very severe or continuous Before</th>
<th>After</th>
<th>Severe or frequent Before</th>
<th>After</th>
<th>Moderate and not frequent Before</th>
<th>After</th>
<th>No pain Before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ebimar</td>
<td>1</td>
<td>0</td>
<td>8</td>
<td>7</td>
<td>17</td>
<td>6</td>
<td>1</td>
<td>14</td>
</tr>
<tr>
<td>A1,0a</td>
<td>2</td>
<td>0</td>
<td>11</td>
<td>2</td>
<td>12</td>
<td>7</td>
<td>1</td>
<td>17</td>
</tr>
</tbody>
</table>

### TABLE 3

**SUMMARY OF RESULTS WITH BARIUM MEALS**

*Ebimar (20 patients)*

<table>
<thead>
<tr>
<th>Before Treatment</th>
<th>After 1-5 mths.</th>
<th>After 6-10 mths.</th>
<th>After 11-15 mths.</th>
<th>On leaving trial after 1-15 months' treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active</td>
<td>19</td>
<td>4 (20%)</td>
<td>3 (15%)</td>
<td>2 (10%)</td>
</tr>
<tr>
<td>Healing</td>
<td>1</td>
<td>13 (65%)</td>
<td>6 (30%)</td>
<td>5 (25%)</td>
</tr>
<tr>
<td>No ulcer</td>
<td>0</td>
<td>3 (15%)</td>
<td>2 (10%)</td>
<td>1 (5%)</td>
</tr>
<tr>
<td>No assessment</td>
<td>0</td>
<td>0</td>
<td>9 (45%)</td>
<td>12 (60%)</td>
</tr>
</tbody>
</table>

*A1,0a (25 patients)*

| Active | 25 | 7 (28%) | 5 (20%) | 3 (12%) | 8 (32%) |
| Healing | 0 | 6 (24%) | 4 (16%) | 4 (16%) | 6 (24%) |
| No ulcer | 0 | 11 (44%) | 3 (12%) | 2 (8%) | 11 (44%) |
| No assessment | 0 | 1 (4%) | 13 (52%) | 16 (64%) | 0 |

### TABLE 4

1. Free of all symptoms
2. Some mild symptoms remain, but no loss of weight, no vomiting; barium meal shows no ulcer
3. All findings improved and no vomiting, no severe pain, but some weight loss or radiological evidence of ulcers remain
4. Some findings improved and none worse
5. No significant improvement

<table>
<thead>
<tr>
<th>A1,0a</th>
<th>Ebimar</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 (15%)</td>
<td>5 (15%)</td>
</tr>
<tr>
<td>3 (12%)</td>
<td>0</td>
</tr>
<tr>
<td>5 (19%)</td>
<td>7 (26%)</td>
</tr>
<tr>
<td>11 (42%)</td>
<td>8 (30%)</td>
</tr>
<tr>
<td>3 (12%)</td>
<td>8 (30%)</td>
</tr>
</tbody>
</table>
but none at the end of the follow-up period.

**General assessment of treatment.** The patients were graded into 5 groups at the end of their treatment, taking into account all recorded symptoms, including vomiting and melæna.

Three patients showed no improvement after aluminium hydroxide and neither did 8 after ebimar, but this difference was not significant. (χ²=2.45, P>0.10). If it is assumed that from the patient’s point of view the treatment was effective only in the first three groups in Table 4, there was no difference between the two groups, 46% improving on aluminium hydroxide and 41% on ebimar.

**Comment**

The results clearly show that many patients with peptic ulceration obtain relief from symptoms and avoid surgery (for some time at least), if treated as out-patients with rest, diet and an antacid or an antipeptic drug. It is not possible however, on the above findings, to conclude that one treatment is more effective than the other. There is no evidence from these trials to suggest that a larger number of patients or a different dosage schedule for either drug might show a clear-cut advantage of one drug over the other. It is, however, possible that a combination of the two drugs (aluminium hydroxide after meals and ebimar an hour or two later) might show an advantage over one or the other drug given alone. Marquez and Garcia (1960) as a result of *in vitro* experiments advises against using a combined tablet.

Two definite points emerge. First, ebimar causes less constipation than aluminium hydroxide; this view is strengthened by the fact that on their diet sheets all patients were advised to take liquid paraffin or milk of magnesia if they became constipated, so that laxatives had not been used more patients might have reported constipation after aluminium hydroxide. The second point is that patients preferred ebimar (either chewed and swallowed or kept between cheek and gum) to aluminium hydroxide gel. Many patients with dentures complained that particles of the latter got under their plates and caused discomfort.

**Summary**

In two blind trials of degraded carrageenan (Ebimar) and aluminium hydroxide gel in the treatment of peptic ulceration, using different dose schedules in the two trials, degraded carrageenan and aluminium hydroxide both appeared to be effective in giving symptomatic relief but neither seemed to influence the natural history of the diseases.

We express our thanks to Evans Medical Ltd., for providing us with the drugs and to their medical and scientific staff for their help. Our thanks go also to the Sisters in the out-patient department of the War Memorial Hospital, Wrexham, and Mrs. Jones and Mrs. Parry for secretarial assistance.

**REFERENCES**


Anderson, W., and Watt, J. (1959b): Inhibition of Peptic Activity. Protection against Histamine Ulceration in the Guinea Pig, and Combination with Gastric Mucin by an Algal Polyanion, *J. Pharm. (Lond.*), 11, 318.


Blind Trial of a Degraded Carrageenin and Aluminium Hydroxide Gel in the Treatment of Peptic Ulceration

P. R. C. Evans, S. Nowell and I. A. P. Thomas

Postgrad Med J 1965 41: 48-52
doi: 10.1136/pgmj.41.471.48

Updated information and services can be found at:
http://pmj.bmj.com/content/41/471/48.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/